Can Base Modifications be Targeted for Cancer Therapy?
Yes, base modifications are promising targets for cancer therapy. Epigenetic drugs that specifically target enzymes involved in adding or removing these modifications are in clinical use or development. Examples include:
2. Histone Deacetylase Inhibitors (HDACis): These drugs, such as vorinostat and romidepsin, inhibit histone deacetylases and are used in the treatment of various cancers.
3. RNA Modifying Enzyme Inhibitors: Though still in early stages, targeting enzymes that modify RNA is an emerging therapeutic strategy.
